FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases

Abstract: Fibroblast growth factor 21 (FGF21) analogs and FGF21 receptor agonists (FGF21RAs) that mimic FGF21 ligand activity constitute the new “FGF21-class” of anti-obesity and anti-diabetic molecules that improve insulin sensitivity, ameliorate hepatosteatosis and promote weight loss. The metabolic actions of FGF21-class proteins in obese mice are attributed to stimulation of brown fat thermogenesis and increased secretion of adiponectin. The therapeutic utility of this class of molecules is being actively investigated in clinical trials for the treatment of type 2 diabetes and non-alcoholic steatohepatitis (NASH). This review is focused on various FGF21-class molecules, their molecular designs and the preclinical and clinical activities. These molecules include modified FGF21 as well as agonistic antibodies against the receptor for FGF21, namely the complex of FGF receptor 1 (FGFR1) and the obligatory coreceptor βKlotho (KLB). In addition, a novel approach to increase endogenous FGF21 activity by inhibiting the FGF21-degrading protease fibroblast activation protein (FAP) is discussed.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases ; volume:30 ; number:2 ; year:2017 ; extent:13 ; Hormone molecular biology and clinical investigation ; 30, Heft 2 (2017) (gesamt 13)

Contributors, Places and Time

• Creator: Sonoda, Junichiro ; Chen, Mark Z. ; Baruch, Amos

Further information

• DOI: 10.1515/hmbci-2017-0002
• URN: urn:nbn:de:101:1-2501230313009.537173569699
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:23 AM CEST